Believe the data

New England Journal of Medicine

Volumn 367, Issue 12, 2012, Pages 1152-1153

  Drazen, Jeffrey M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL STUDY; DATA ANALYSIS; DIABETES MELLITUS; EDITORIAL; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MEDICAL INFORMATION; NATIONAL HEALTH ORGANIZATION; PATIENT CARE; PATIENT PARTICIPATION; PRIORITY JOURNAL; RESEARCH SUBJECT; TRANSLATIONAL RESEARCH;

EID: 84866353890     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1207121     Document Type: Editorial

References (8)

1. Kesselheim AS, Robertson CT, Myers JA, et al. A randomized study of how physicians interpret research funding disclosures. N Engl J Med 2012;367:1119-27.
2. Dyer O. GlaxoSmithKline faces US lawsuit over concealment of trial results. BMJ 2004;328:1395.
3. Tanne JH. Merck pays $1bn penalty in relation to promotion of rofecoxib. BMJ 2011;343:d7702.
4. Idem. GSK is accused of trying to suppress editorial on rosiglitazone. BMJ 2010;340:c2654.
5. Frost P. Abbott Laboratories settles Depakote case for $1.6 billion. Chicago Tribune. May 8, 2012.
6. Harris G. Pfizer to pay $430 million over promoting drug to doctors. New York Times. May 14, 2004.
7. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1.
8. Drazen JM, de Leeuw PW, Laine C, et al. Toward more uniform conflict disclosures - the updated UCMJE conflict of interest reporting form. N Engl J Med 2010;363:188-9.